A
AmacaThera
Commercializing hydrogel-based drug delivery platforms
About AmacaThera
AmacaThera is a biotechnology company based in Toronto, specializing in the development and commercialization of a unique, injectable hydrogel platform technology. This technology is designed to provide sustained therapeutic release, outperforming other available technologies in the market. The company's hydrogel is composed of two main materials that exhibit properties such as shear thinning and inverse thermal gelling, making it highly effective for various medical applications. AmacaThera primarily serves the healthcare sector, targeting medical professionals and institutions that require advanced drug delivery systems. The company operates in the biotechnology market, focusing on innovative solutions for therapeutic delivery. AmacaThera's business model revolves around research and development, followed by commercialization of their hydrogel technology. Revenue is generated through partnerships, licensing agreements, and direct sales of their hydrogel products. The company has also secured non-dilutive funding to support its growth and development initiatives. AmacaThera's achievements include the publication of 27 academic research papers on their technology and validation from independent groups through additional publications. The company is actively seeking partnerships to expand the reach and application of their hydrogel platform.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Toronto, Canada
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 88.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $2.9M | $52M | BDC Capital · StandUp Ventures · Inveready · MaRS Investment Accelerator Fund | ↗ |
| GRANT✓Other financing | Jan 2023 | $0 | — | Johnson & Johnson Innovation | ↗ |
Growth signals
Latest recorded traffic for AmacaThera is 2.5K monthly website visits, up 941.7% over the last three months. AmacaThera's team grew 53.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
Creative Destruction Lab
Ontario Bioscience Industry Organization- VBViva BioInnovator
- SBSprout BioVentures
Lumira Ventures- GPGrey Sky Venture Partners
University of Waterloo Student Venture Fund
Johnson & Johnson Innovation
Series A6 investors entered at this stage
StandUp Ventures
MBX Capital
BDC Capital
Inveready
MaRS Investment Accelerator Fund- CMCR Capital Management
Series B and later1 investor entered at this stage
- XMXiamen Changrong Investment Management
Other known investors2 additional known investors
University of Waterloo
Business Development Bank of Canada
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AmacaThera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AmacaThera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.